---
title: "Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here's How to Buy Without the Risk"
description: "Johnson & Johnson (JNJ) will report Q4 earnings on January 21, with analysts predicting revenue of $24.16 billion and earnings of $2.49 per share. Investors may consider ETFs like iShares U.S. Pharmac"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272977148.md"
published_at: "2026-01-19T13:14:04.000Z"
---

# Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here's How to Buy Without the Risk

> Johnson & Johnson (JNJ) will report Q4 earnings on January 21, with analysts predicting revenue of $24.16 billion and earnings of $2.49 per share. Investors may consider ETFs like iShares U.S. Pharmaceuticals ETF (IHE) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) for exposure to JNJ without direct stock risk. The IHE ETF, which holds 23% of JNJ, has gained 28.09% over six months and has a Moderate Buy consensus rating with a price target suggesting 19.24% upside potential.

Johnson & Johnson (JNJ) is set to report its Q4 earnings on January 21. Analysts expect revenue of about $24.16 billion, up 7.3% year‑over‑year, and earnings of $2.49 per share, reflecting a 22.1% increase from last year. With expectations running high, this could be the right moment for investors to seek exposure to JNJ's potential upside, particularly through exchange-traded funds (ETFs) that offer diversified exposure without the risk of holding the stock directly.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Investors seeking exposure to JNJ stock may consider iShares U.S. Pharmaceuticals ETF (IHE) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH). Let's take a deeper look at these two ETFs.

## **iShares U.S. Pharmaceuticals ETF (IHE)**

The IHE ETF focuses specifically on large U.S. pharmaceutical companies. The fund invests in a focused group of major drug companies known for steady cash flow, solid pipelines, and stable performance even when markets are volatile. Importantly, JNJ stock accounts for 23% of the IHE ETF's total holdings.

Apart from JNJ, some of the top stocks in the IHE ETF are Eli Lilly (LLY), Merck (MRK), and Bristol-Myers Squibb (BMY). Overall, the ETF has $971.66 million in assets under management (AUM). Also, it has an expense ratio of 0.38%. Over the past six months, the IHE ETF has gained 28.09%.

On TipRanks, IHE has a Moderate Buy consensus rating based on 52 Buys, two Holds, and one Sell assigned in the last three months. At $102.17, the average IHE ETF price target implies 19.24% upside potential.

### Related Stocks

- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)
- [PBPH.US - Portfolio Bldg Blck Wld Phrm &BtchIdxETF](https://longbridge.com/en/quote/PBPH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 强生｜10-K：2025 财年营收 942 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275658131.md) |
| Siligmueller & Norvid Wealth Advisors LLC 收购了强生公司 $JNJ 的新股份 | Siligmueller & Norvid Wealth Advisors LLC 在第三季度收购了强生（NYSE: JNJ）的新股份，购买了 4,823 股，价值约为 896,000 美元。其他机构投资者也增加了在该公司的持仓。分析师对强 | [Link](https://longbridge.com/en/news/276513422.md) |
| Madrigal 制药｜8-K：2025 财年 Q4 营收 3.21 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| 期权热点｜上周五 UVIX 涨 3%，部分看涨期权飙升 150% | 美东时间 02 月 13 日，2 倍做多恐慌指数期货 ETF 期权总成交 86443 张，看涨期权占比 82%，看跌期权占比 17%。 | [Link](https://longbridge.com/en/news/276030214.md) |
| Uniting Wealth Partners LLC 收购了 5,056 股强生公司$JNJ 股票 | 联合财富伙伴公司（Uniting Wealth Partners LLC）在第三季度收购了 5,056 股强生（Johnson & Johnson，NYSE: JNJ），价值约为 938,000 美元。其他机构投资者也调整了他们的持仓，SO | [Link](https://longbridge.com/en/news/276006840.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
